HUTCHMED climbs after starting HMPL-A830 global solid-tumor trial
Shares rose 2.6% to HK$22.5 after the company said it initiated the Phase Ia part of a global clinical trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.